StockNews.com Upgrades Inovio Pharmaceuticals (NASDAQ:INO) to Hold

StockNews.com upgraded shares of Inovio Pharmaceuticals (NASDAQ:INO) from a sell rating to a hold rating in a research report sent to investors on Thursday.

Several other research analysts have also commented on the company. JMP Securities reissued a “market outperform” rating and set a $18.00 price objective on shares of Inovio Pharmaceuticals in a report on Friday, January 10th. Royal Bank of Canada decreased their price target on shares of Inovio Pharmaceuticals from $6.00 to $5.00 and set a “sector perform” rating on the stock in a report on Wednesday, March 19th. Finally, HC Wainwright reaffirmed a “neutral” rating and set a $3.00 price objective on shares of Inovio Pharmaceuticals in a report on Wednesday, March 19th. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the company. Based on data from MarketBeat, Inovio Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $12.20.

Inovio Pharmaceuticals Trading Up 1.2 %

Shares of Inovio Pharmaceuticals stock opened at $1.74 on Thursday. The company’s 50-day moving average price is $1.88 and its 200-day moving average price is $3.08. The company has a market cap of $63.80 million, a price-to-earnings ratio of -0.44 and a beta of 1.84. Inovio Pharmaceuticals has a 12-month low of $1.42 and a 12-month high of $13.44.

Inovio Pharmaceuticals (NASDAQ:INO) last issued its quarterly earnings data on Tuesday, March 18th. The biopharmaceutical company reported ($0.69) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.87) by $0.18. The business had revenue of $0.12 million during the quarter, compared to analysts’ expectations of $0.03 million. On average, sell-side analysts predict that Inovio Pharmaceuticals will post -4.23 earnings per share for the current year.

Institutional Trading of Inovio Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in INO. Deep Track Capital LP boosted its holdings in Inovio Pharmaceuticals by 72.9% during the 4th quarter. Deep Track Capital LP now owns 3,119,162 shares of the biopharmaceutical company’s stock valued at $5,708,000 after acquiring an additional 1,314,796 shares during the period. Stonepine Capital Management LLC purchased a new stake in shares of Inovio Pharmaceuticals during the fourth quarter valued at approximately $1,922,000. AIGH Capital Management LLC bought a new position in shares of Inovio Pharmaceuticals in the fourth quarter worth approximately $1,197,000. Bank of America Corp DE raised its holdings in Inovio Pharmaceuticals by 1,035.2% during the 4th quarter. Bank of America Corp DE now owns 640,987 shares of the biopharmaceutical company’s stock valued at $1,173,000 after buying an additional 584,521 shares during the last quarter. Finally, Geode Capital Management LLC boosted its position in Inovio Pharmaceuticals by 1.1% during the 4th quarter. Geode Capital Management LLC now owns 628,505 shares of the biopharmaceutical company’s stock valued at $1,150,000 after buying an additional 6,874 shares during the period. 26.79% of the stock is currently owned by hedge funds and other institutional investors.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.